enGene Initiates LEGEND Study of EG-70 in BCG-Unresponsive NMIBC Patients
The LEGEND study will evaluate the safety and efficacy of EG-70 in patients with BCG-unresponsive NMIBC.
Asset / Drug
Drug and asset intelligence for enGene with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.